查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592901

感染疾病藥物市場：按藥物、給藥途徑、疾病、分銷管道和最終用戶分類 - 全球預測 2025-2030

Infectious Disease Therapeutics Market by Drug (Antibiotics, Antifungal Drugs, Antiparasitic Drugs), Route of Administration (Intravenous, Oral, Topical), Disease, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，感染疾病治療市場估值為1,162.1億美元，預計到2024年將達到1,212.7億美元，複合年成長率為4.41%，到2030年預計將達到1,572.8億美元。

感染疾病藥物是指為對抗病毒、細菌、真菌和寄生蟲等病原體引起的感染疾病而開發的治療方法和藥物。這包括抗病毒藥物、抗菌、抗真菌和抗寄生蟲藥物，以及疫苗和個人化醫療。感染疾病的持續爆發、新出現的感染疾病以及抗藥性菌株數量的增加凸顯了對這一治療領域的需求，這需要創新的治療方法來保護公眾健康。應用範圍廣泛，包括醫院、診所和居家醫療，最終用戶包括醫療專業人員和患者。市場的關鍵成長要素包括感染疾病率上升、大量研發投資以及政府促進先進醫療基礎設施的措施。此外，COVID-19 大流行凸顯了快速開發疫苗和先進治療解決方案的必要性，從而創造了積極的資金籌措和研究動力。值得注意的機會在於針對抗生素抗藥性感染疾病的創新藥物的開發、廣譜抗病毒藥物以及促進個人化治療的基因組醫學的進步。由於醫療保健服務的改善和感染疾病患者數量的增加，亞太和非洲的開拓市場具有巨大的成長潛力。儘管有這樣的前景，該領域仍面臨著高昂的研發成本、複雜的監管環境以及病原體突變的不可預測性等挑戰，這些都使藥物功效變得複雜。為了克服這些挑戰，建議公共和私營部門之間加強合作並加快核准流程。對於業務擴張至關重要的創新領域包括基因治療、mRNA疫苗技術以及利用人工智慧的藥物發現方法，有望取得突破性成果。該市場的特點是競爭激烈，大量全球和區域參與者爭奪技術優勢和市場佔有率，需要持續創新和策略聯盟。將研究快速轉化為實際治療方法對於有效應對不斷變化的感染疾病情況至關重要。

主要市場統計
基準年[2023] 1162.1億美元
預測年份 [2024] 1212.7億美元
預測年份 [2030] 1572.8億美元
複合年成長率（%） 4.41%

市場動態：快速發展的感染疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變感染疾病藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界各地感染疾病的擴大
    • 政府為減輕感染疾病負擔所做的努力和迅速行動
    • 專利到期和學名藥進入增加
  • 市場限制因素
    • 感染疾病藥物對健康的不良影響
  • 市場機會
    • 感染疾病開發新藥投入快速增加
    • 感染疾病免疫治療的最新進展
  • 市場挑戰
    • 感染疾病管理替代治療方法的可用性

波特五力：駕馭感染疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解感染疾病治療市場的外部影響

外部宏觀環境因素對感染疾病藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解感染疾病治療藥物市場的競爭狀況

感染疾病治療藥物市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣感染疾病治療市場供應商的績效評估

FPNV 定位矩陣是評估感染疾病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪感染疾病治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，感染疾病藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病在世界各地的傳播加劇
      • 政府為減輕感染疾病負擔所做的努力和迅速行動
      • 專利到期和學名藥的增加引入
    • 抑制因素
      • 感染疾病藥物造成的健康損害
    • 機會
      • 感染疾病開發新藥投入快速增加
      • 感染疾病免疫治療的最新進展
    • 任務
      • 感染疾病管理替代治療方法的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章感染疾病治療藥品市場（依藥品）

  • 抗生素
  • 抗真菌藥物
  • 抗寄生蟲藥
  • 抗病毒藥物

第7章感染疾病治療藥物市場：依給藥途徑

  • 靜脈
  • 口服
  • 話題

第8章感染疾病治療藥物市場：依疾病分類

  • 肝炎
  • HIV
  • 流感
  • 瘧疾
  • 結核

第9章感染疾病治療藥物市場：依通路分類

  • 離線
  • 線上

第10章感染疾病治療藥物市場：依最終使用者分類

  • 居家照護設施
  • 醫院/診所

第11章 北美和南美感染疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區感染疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲感染疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chimerix, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Chemical Group Corporation
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market was valued at USD 116.21 billion in 2023, expected to reach USD 121.27 billion in 2024, and is projected to grow at a CAGR of 4.41%, to USD 157.28 billion by 2030.

Infectious Disease Therapeutics refers to treatments and drugs developed to combat infectious diseases caused by pathogens such as viruses, bacteria, fungi, and parasites. The scope of this market is broad, enveloping antiviral, antibacterial, antifungal, and antiparasitic agents, alongside vaccines and personalized medicine. The necessity of this therapeutics segment is underscored by continual outbreaks, emerging infectious diseases, and an increasing prevalence of drug-resistant strains, which require innovative treatments to safeguard public health. Applications extend across hospitals, clinics, and home healthcare settings, with end-users including healthcare providers and patients. Key growth influencers in the market include the rising incidence of infectious diseases, substantial R&D investments, and government initiatives promoting advanced healthcare infrastructure. Furthermore, the COVID-19 pandemic has highlighted the critical need for rapid vaccine development and advanced therapeutic solutions, creating invigorated funding and research momentum. Noteworthy opportunities lie in the development of innovative drugs targeting antibiotic-resistant infections, broad-spectrum antivirals, and advancements in genomic medicine facilitating tailored treatments. Developing markets in Asia-Pacific and Africa present considerable growth potential due to improving healthcare access and rising infectious disease cases. Despite these prospects, the sector faces challenges such as high R&D costs, complex regulatory landscapes, and the unpredictability of pathogen mutation, complicating drug efficacy. To overcome these, robust public-private collaborations and accelerated approval processes are recommended. Innovation areas crucial for business expansion include gene therapy, mRNA vaccine technologies, and AI-driven drug discovery methods, which hold promise for breakthrough results. The market is characterized by intense competition due to a plethora of global and regional players striving for technological superiority and market share, necessitating continuous innovation and strategic alliances. Emphasizing the swift translation of research into actionable therapeutics remains imperative to meet the evolving landscape of infectious diseases effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 116.21 billion
Estimated Year [2024] USD 121.27 billion
Forecast Year [2030] USD 157.28 billion
CAGR (%) 4.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious disease across the globe
    • Government initiatives and prompt actions to reduce the burden of infectious disease
    • Increasing number of patent expirations and entry of generic drugs
  • Market Restraints
    • Adverse health outcomes of infectious disease drugs
  • Market Opportunities
    • Surging investments for development of new drugs to treat infectious diseases
    • Recent advances in immunotherapies against infectious disease
  • Market Challenges
    • Availability of alternative treatments for infectious disease management

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Disease Therapeutics Market

A detailed market share analysis in the Infectious Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Disease Therapeutics Market

A strategic analysis of the Infectious Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Allergan PLC, Amgen Inc., Astellas Pharma US, Inc., AstraZeneca PLC, Bayer AG, BioCryst Pharmaceuticals, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Chimerix, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Chemical Group Corporation, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Antibiotics, Antifungal Drugs, Antiparasitic Drugs, and Antiviral Drugs.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Disease, market is studied across Hepatitis, HIV, Influenza, Malaria, and Tuberculosis.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Homecare Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious disease across the globe
      • 5.1.1.2. Government initiatives and prompt actions to reduce the burden of infectious disease
      • 5.1.1.3. Increasing number of patent expirations and entry of generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health outcomes of infectious disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging investments for development of new drugs to treat infectious diseases
      • 5.1.3.2. Recent advances in immunotherapies against infectious disease
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatments for infectious disease management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infectious Disease Therapeutics Market, by Drug

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Antifungal Drugs
  • 6.4. Antiparasitic Drugs
  • 6.5. Antiviral Drugs

7. Infectious Disease Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Infectious Disease Therapeutics Market, by Disease

  • 8.1. Introduction
  • 8.2. Hepatitis
  • 8.3. HIV
  • 8.4. Influenza
  • 8.5. Malaria
  • 8.6. Tuberculosis

9. Infectious Disease Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Infectious Disease Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Homecare Facilities
  • 10.3. Hospitals & Clinics

11. Americas Infectious Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Infectious Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Infectious Disease Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Allergan PLC
  • 4. Amgen Inc.
  • 5. Astellas Pharma US, Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. BioCryst Pharmaceuticals, Inc.
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. Celgene Corporation
  • 13. Chimerix, Inc.
  • 14. Eli Lilly and Company
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline PLC
  • 17. Johnson & Johnson Services, Inc.
  • 18. Merck & Co., Inc.
  • 19. Mitsubishi Chemical Group Corporation
  • 20. Mylan N.V.
  • 21. Novartis AG
  • 22. Novo Nordisk A/S
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPARASITIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023